Xellera Therapeutics Asia Limited

Novoheart is a global stem cell biotechnology company that is dedicated to develop and engineer bio-artificial human heart prototypes using a combination of world’s first and state-of-the-art stem cell and tissue engineering approaches.

Our mission and vision are to revolutionize drug discovery and development of heart therapeutics with our range of proprietary bio-engineered human heart constructs , and to further develop them into transplantable heart grafts for cell-based regenerative therapies with superior safety and efficacy.

Novoheart develops products and provides services with a focus on engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardiotoxicity screening, disease modeling and future therapeutic applications.

Products and services include, but are not limited to, set-up and maintenance of proprietary physiological tissue systems that are supported by our in-house hardware (to measure physiological signals such as electrocardiograms, muscle contraction force, etc.) and software (to provide a user-friendly interface to display outputs and control the systems).

Overall, the unique technologies in Novoheart’s products and services have been designed to reduce the time, cost, use of animal models and increase human safety to facilitate pharmaceutical discovery and development. Novoheart is currently working with leading academic and pharmaceutical partners to innovate drug discovery and toxicity screening protocols.